60 DEGREES PHARMACEUTICALS, INC. — Form 8-K
Filed July 20, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 28/100
What the filing says
60 Degrees Pharmaceuticals (market cap ~$3.3M, 2.66M shares at $1.78) released an investor presentation dated July 20, 2026, describing its malaria prophylaxis product ARAKODA (tafenoquine, FDA-approved 2018, available 2019) and clinical programs for babesiosis. The company is executing three ongoing babesiosis trials (NCT06207370 for hospitalized patients with interim analysis targeted before October 30, 2026; NCT06478641 for immunosuppressed relapsing patients; NCT06656351 for chronic babesiosis), targeting supplemental NDA submission by April 2027. Recent financing includes a $5M public offering at $7.60/share (July 2025) and ~$4M from an ATM offering (October 2025–March 2026). The presentation targets profitability in 2027–2028 based on continued malaria sales growth and positive babesiosis outcomes.
Why this rating
Investor presentation is standard disclosure; no material corporate event (M&A, financing, restatement, or trial result). Clinical trial progress and financing already occurred. Routine forward-looking investor communication.
See more from July 20, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.